172 related articles for article (PubMed ID: 11160713)
21. Receptor (CD46)- and replication-mediated interleukin-6 induction by measles virus in human astrocytoma cells.
Ghali M; Schneider-Schaulies J
J Neurovirol; 1998 Oct; 4(5):521-30. PubMed ID: 9839649
[TBL] [Abstract][Full Text] [Related]
22. Reduced ability of hemagglutinin of the CAM-70 measles virus vaccine strain to use receptors CD46 and SLAM.
Kato S; Ohgimoto S; Sharma LB; Kurazono S; Ayata M; Komase K; Takeda M; Takeuchi K; Ihara T; Ogura H
Vaccine; 2009 Jun; 27(29):3838-48. PubMed ID: 19490984
[TBL] [Abstract][Full Text] [Related]
23. Measles virus receptor properties are shared by several CD46 isoforms differing in extracellular regions and cytoplasmic tails.
Gerlier D; Loveland B; Varior-Krishnan G; Thorley B; McKenzie IF; Rabourdin-Combe C
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2163-71. PubMed ID: 8077916
[TBL] [Abstract][Full Text] [Related]
24. A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism.
Johnston IC; ter Meulen V; Schneider-Schaulies J; Schneider-Schaulies S
J Virol; 1999 Aug; 73(8):6903-15. PubMed ID: 10400788
[TBL] [Abstract][Full Text] [Related]
25. Differential receptor usage by measles virus strains.
Bartz R; Firsching R; Rima B; ter Meulen V; Schneider-Schaulies J
J Gen Virol; 1998 May; 79 ( Pt 5)():1015-25. PubMed ID: 9603316
[TBL] [Abstract][Full Text] [Related]
26. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
27. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Anderson BD; Nakamura T; Russell SJ; Peng KW
Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
[TBL] [Abstract][Full Text] [Related]
28. Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins.
Tatsuo H; Okuma K; Tanaka K; Ono N; Minagawa H; Takade A; Matsuura Y; Yanagi Y
J Virol; 2000 May; 74(9):4139-45. PubMed ID: 10756026
[TBL] [Abstract][Full Text] [Related]
29. Contributions of matrix and large protein genes of the measles virus edmonston strain to growth in cultured cells as revealed by recombinant viruses.
Tahara M; Takeda M; Yanagi Y
J Virol; 2005 Dec; 79(24):15218-25. PubMed ID: 16306593
[TBL] [Abstract][Full Text] [Related]
30. V domain of human SLAM (CDw150) is essential for its function as a measles virus receptor.
Ono N; Tatsuo H; Tanaka K; Minagawa H; Yanagi Y
J Virol; 2001 Feb; 75(4):1594-600. PubMed ID: 11160657
[TBL] [Abstract][Full Text] [Related]
31. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
32. A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells.
Mourez T; Mesel-Lemoine M; Combredet C; Najburg V; Cayet N; Tangy F
Virology; 2011 Oct; 419(2):117-25. PubMed ID: 21890164
[TBL] [Abstract][Full Text] [Related]
33. The ectodomain of measles virus envelope glycoprotein does not gain access to the cytosol and MHC class I presentation pathway following virus-cell fusion.
Cardoso AI; Gerlier D; Wild TF; Rabourdin-Combe C
J Gen Virol; 1996 Nov; 77 ( Pt 11)():2695-9. PubMed ID: 8922462
[TBL] [Abstract][Full Text] [Related]
34. Recombinant wild-type and edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity.
Takeuchi K; Takeda M; Miyajima N; Kobune F; Tanabayashi K; Tashiro M
J Virol; 2002 May; 76(10):4891-900. PubMed ID: 11967306
[TBL] [Abstract][Full Text] [Related]
35. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
[TBL] [Abstract][Full Text] [Related]
37. Efficient MHC class II-restricted presentation of measles virus to T cells relies on its targeting to its cellular receptor human CD46 and involves an endosomal pathway.
Gerlier D; Trescol-Biémont MC; Varior-Krishnan G; Naniche D; Fugier-Vivier I; Rabourdin-Combe C
Cell Biol Int; 1994 May; 18(5):315-20. PubMed ID: 8049676
[TBL] [Abstract][Full Text] [Related]
38. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
39. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion.
Wild TF; Malvoisin E; Buckland R
J Gen Virol; 1991 Feb; 72 ( Pt 2)():439-42. PubMed ID: 1993882
[TBL] [Abstract][Full Text] [Related]
40. Measles virus and CD46.
Kemper C; Atkinson JP
Curr Top Microbiol Immunol; 2009; 329():31-57. PubMed ID: 19198561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
